CRP and rheumatoid arthritis: The maximal predictive value of the ACR20 response to olokizumab at week 24 was achieved by the inclusion of clinical factors (age, duration of the disease at the time of inclusion in the study, and initial RA activity according to the DAS28-CRP) with genetic polymorphisms: AUC = 0.9415 (95% CI: 0.8902–0.9927; p < 0.0001) (Figure 1).